Concepedia

David Taber

DT

16

Publications

1.5K

Citations

13

H-Index

1954

Active since

Affiliations

University of Chicago(Current)

Northern Indiana Cancer Research Consortium

Hematology Oncology Associates

Cancer Care Specialists of Illinois

Hoosier Cancer Research Network (United States)

David Taber is an author at University of Chicago specializing in medicine, oncology, and radiation oncology.

Top concepts

Publications per year

1954–2012

16

Publications

16

Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer

Hedy L. Kindler, Gregory Friberg, D. A. Singh et al. · Journal of Clinical Oncology · 2005 · 458 citations · Full text

Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma

Hedy L. Kindler, Theodore Karrison, David R. Gandara et al. · Journal of Clinical Oncology · 2012 · 256 citations · Full text

Flavopiridol, A Novel Cyclin-Dependent Kinase Inhibitor, in Metastatic Renal Cancer: A University of Chicago Phase II Consortium Study

Walter M. Stadler, Nicholas J. Vogelzang, Robert J. Amato et al. · Journal of Clinical Oncology · 2000 · 208 citations

Phase II Trial of Weekly Intravenous Gemcitabine With Continuous Infusion Fluorouracil in Patients With Metastatic Renal Cell Cancer

Brian I. Rini, Nicholas J. Vogelzang, M Dumas et al. · Journal of Clinical Oncology · 2000 · 155 citations

Phase II Trial of PS-341 in Patients With Renal Cell Cancer: A University of Chicago Phase II Consortium Study

Nancy B. Davis, David Taber, Rafat Ansari et al. · Journal of Clinical Oncology · 2003 · 141 citations · Full text

Rows per page

1–5 of 16